{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:42:29Z","timestamp":1790296949094,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41416-018-0368-3","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:02:51Z","timestamp":1549929771000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma"],"prefix":"10.1038","volume":"120","author":[{"given":"Martha","family":"Foltyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Luisa","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja I.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4391","authenticated-orcid":false,"given":"Benedikt","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-6910","authenticated-orcid":false,"given":"Patrick N.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6290","authenticated-orcid":false,"given":"Michael W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"Suppl. 4","key":"368_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 16(Suppl. 4), iv1\u201363 (2014).","journal-title":"Neuro Oncol."},{"key":"368_CR2","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","volume":"64","author":"H Ohgaki","year":"2004","unstructured":"Ohgaki, H. et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64, 6892\u20136899 (2004).","journal-title":"Cancer Res."},{"key":"368_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"368_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/nos273","volume":"15","author":"M Weller","year":"2013","unstructured":"Weller, M., Cloughesy, T., Perry, J. R. & Wick, W. Standards of care for treatment of recurrent glioblastoma\u2014are we there yet? Neuro Oncol. 15, 4\u201327 (2013).","journal-title":"Neuro Oncol."},{"key":"368_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L. et al. Bevacizumab plus radiotherapy\u2014temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709\u2013722 (2014).","journal-title":"N. Engl. J. Med."},{"key":"368_CR6","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","volume":"8","author":"A Rapisarda","year":"2009","unstructured":"Rapisarda, A. et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8, 1867\u20131877 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"368_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"368_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2012.07781.x","volume":"122","author":"C Happold","year":"2012","unstructured":"Happold, C. et al. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J. Neurochem. 122, 444\u2013455 (2012).","journal-title":"J. Neurochem."},{"key":"368_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(02)00706-2","volume":"10","author":"LW Ellisen","year":"2002","unstructured":"Ellisen, L. W. et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell 10, 995\u20131005 (2002).","journal-title":"Mol. Cell"},{"key":"368_CR10","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/MCB.22.7.2283-2293.2002","volume":"22","author":"T Shoshani","year":"2002","unstructured":"Shoshani, T. et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell Biol. 22, 2283\u20132293 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"368_CR11","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1128\/MCB.25.14.5834-5845.2005","volume":"25","author":"A Sofer","year":"2005","unstructured":"Sofer, A., Lei, K., Johannessen, C. M. & Ellisen, L. W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell Biol. 25, 5834\u20135845 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"368_CR12","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1101\/gad.1256804","volume":"18","author":"J Brugarolas","year":"2004","unstructured":"Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex. Genes Dev. 18, 2893\u20132904 (2004).","journal-title":"Genes Dev."},{"key":"368_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1101\/gad.1617608","volume":"22","author":"MP DeYoung","year":"2008","unstructured":"DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. & Ellisen, L. W. Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239\u2013251 (2008).","journal-title":"Genes Dev."},{"key":"368_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"issue":"Part 6","key":"368_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/brain\/awp093","volume":"132","author":"MW Ronellenfitsch","year":"2009","unstructured":"Ronellenfitsch, M. W. et al. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 132(Part 6), 1509\u20131522 (2009).","journal-title":"Brain"},{"key":"368_CR16","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1093\/brain\/awx196","volume":"140","author":"AL Thiepold","year":"2017","unstructured":"Thiepold, A. L. et al. Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. Brain 140, 2623\u20132638 (2017).","journal-title":"Brain"},{"key":"368_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11523-010-0154-5","volume":"5","author":"MW Ronellenfitsch","year":"2010","unstructured":"Ronellenfitsch, M. W., Steinbach, J. P. & Wick, W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Target Oncol. 5, 183\u2013191 (2010).","journal-title":"Target Oncol."},{"issue":"Part 4","key":"368_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/brain\/awq042","volume":"133","author":"S Seidel","year":"2010","unstructured":"Seidel, S. et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133(Part 4), 983\u2013995 (2010).","journal-title":"Brain"},{"key":"368_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).","journal-title":"Genome Biol."},{"key":"368_CR20","doi-asserted-by":"publisher","first-page":"e94921","DOI":"10.1371\/journal.pone.0094921","volume":"9","author":"S Fischer","year":"2014","unstructured":"Fischer, S. et al. Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic Acid. PLoS ONE 9, e94921 (2014).","journal-title":"PLoS ONE"},{"key":"368_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/neuonc\/now247","volume":"19","author":"RL Bowman","year":"2017","unstructured":"Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. & Squatrito, M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19, 139\u2013141 (2017).","journal-title":"Neuro Oncol."},{"key":"368_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0167-8140(99)00121-8","volume":"53","author":"DR Collingridge","year":"1999","unstructured":"Collingridge, D. R., Piepmeier, J. M., Rockwell, S. & Knisely, J. P. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother. Oncol. 53, 127\u2013131 (1999).","journal-title":"Radiother. Oncol."},{"key":"368_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266\u2013276 (2001).","journal-title":"J. Natl. Cancer Inst."},{"key":"368_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1385\/MO:18:4:243","volume":"18","author":"P Vaupel","year":"2001","unstructured":"Vaupel, P., Thews, O. & Hoeckel, M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18, 243\u2013259 (2001).","journal-title":"Med. Oncol."},{"key":"368_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1073\/pnas.1314469111","volume":"111","author":"M Weiler","year":"2014","unstructured":"Weiler, M. et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc. Natl Acad. Sci. USA 111, 409\u2013414 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Part 5","key":"368_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter, K. L. et al. Corticosteroids compromise survival in glioblastoma. Brain 139(Part 5), 1458\u20131471 (2016).","journal-title":"Brain"},{"key":"368_CR27","unstructured":"Chinnaiyan, P. et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 20, 666\u2013673 (2017)."},{"key":"368_CR28","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","volume":"22","author":"W Wick","year":"2016","unstructured":"Wick, W. et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin. Cancer Res. 22, 4797\u20134806 (2016).","journal-title":"Clin. Cancer Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0368-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:05Z","timestamp":1684616645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0368-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0368-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"25 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The human cell lines used in this study are all commercially or academically available and were not generated in the course of this study, and therefore no ethics approval was necessary for the cell line experiments. The anonymised patient survival data are in whole based upon data generated by the TCGA Research Network:  and are available without limitations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The GlioVis platform<sup>21<\/sup> is available online at:  and the TCGA datasets for glioblastoma (TCGA_GBM) and low-grade gliomas (TCGA_LGG) (generated by the TCGA Research Network: ) are accessible via the website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}